By Nana O 
Immune therapy has revolutionized cancer treatment, offering new hope for patients by harnessing the body’s own defenses to combat malignancies. However, a persistent challenge remains: many tumors possess an uncanny ability to evade these powerful therapies, often by masquerading as healthy tissue. This intricate camouflage allows cancer cells to hide in plain sight, rendering them invisible to the immune system. Now, a groundbreaking study from the University of California, San Francisco (UCSF) has illuminated a novel mechanism by which certain cancers, including the notoriously aggressive brain cancer known as glioma, create unique molecular signatures. These newly identified cancer-specific proteins, termed antigens, hold immense promise for accelerating the development of highly effective immunotherapies capable of targeting and eradicating even the most treatment-resistant tumors.
This pivotal research, supported by grants from the National Institutes of Health, was published in the esteemed scientific journal Nature on February 19th. The findings represent a significant leap forward in our understanding of cancer biology and open a new avenue for therapeutic intervention.
The Genesis of Novel Antigens: A Tale of RNA Splicing Errors
At the heart of this discovery lies a fundamental cellular process known as RNA splicing. This intricate biological mechanism acts as a cellular editor, meticulously controlling how RNA molecules—the blueprints for protein synthesis—are assembled from smaller segments. The UCSF research team found that in a variety of cancers, including those affecting the brain, prostate, liver, and colon, this splicing process goes awry. Tumors exhibit a tendency to splice together disparate pieces of RNA, generating entirely new and previously unseen RNA molecules. Crucially, these aberrant RNA sequences are entirely absent in healthy tissues, making them ideal candidates for cancer-specific targets.
The consequence of these splicing errors is the production of novel proteins, or antigens, that are not found in normal cells. Some of these newly synthesized antigens emerge on the surface of tumor cells, effectively creating a beacon that the immune system can recognize. This discovery provides a direct entry point for developing immunotherapies designed to specifically target these cancer-specific markers.
The researchers then took this discovery a significant step further. They successfully engineered immune T-cells, a critical component of the adaptive immune system, to recognize these newly identified antigens. In laboratory experiments, these engineered T-cells demonstrated a remarkable ability to seek out and destroy glioma cells, showcasing the therapeutic potential of this approach.
The implications of these findings are far-reaching. The identification of antigens arising from alternative RNA splicing could dramatically expand the repertoire of targets available for immunotherapy. This, in turn, could translate into a wider array of treatment options for patients battling a broad spectrum of cancers, offering renewed hope for those with limited prognoses.
A Glimmer of Hope for Stubborn Cancers
Dr. Hideho Okada, MD, PhD, a distinguished professor of neurosurgery at UCSF and co-corresponding author of the study, expressed optimism about the immediate applicability of these findings. "We believe these first antigens could be actionable in the near future, leading to new therapies for glioma patients," he stated. "But they are the tip of the iceberg, and we’re excited to look into many more from the data we generated." This sentiment underscores the vast potential that lies within the generated dataset, hinting at a wealth of future discoveries.
The current landscape of precision medicine largely relies on two main strategies: drugs that target specific mutated proteins driving cancer growth, or immunotherapies that direct the immune system to recognize cancer-related antigens. However, a significant hurdle exists, as many tumors lack these readily identifiable mutant proteins or antigens. Furthermore, even when present, these targets may not encompass the entirety of a tumor, leaving some cancer cells to escape treatment.
Dr. Joe Costello, PhD, another professor of neurosurgery at UCSF and co-corresponding author, elaborated on this critical challenge. "One of the reasons we think a lot of glioma therapies fail is that they only target one part of the tumor. The rest of the tumor escapes unscathed," he explained. "These new antigens lift us over that major hurdle of brain tumor heterogeneity." Tumor heterogeneity, the variation of cells within a single tumor, has long been a formidable obstacle in cancer treatment, as different cells within the tumor can exhibit distinct molecular characteristics and respond differently to therapies.
The Hunt for Novel Targets: A Deep Dive into RNA Sequencing Data
The journey to discover these novel antigens began with a meticulous investigation into RNA splicing. Dr. Darwin Kwok, PhD, a former PhD graduate from the Okada and Costello labs and a current UCSF medical student, spearheaded this effort. Recognizing that while DNA mutations have been a primary focus for cancer therapies, he hypothesized that alterations in RNA splicing could also lead to the generation of unique cancer-specific antigens.
To test this hypothesis, Dr. Kwok delved into an extensive repository of RNA sequencing data from thousands of tumors. This data was sourced from The Cancer Genome Atlas (TCGA), a monumental project funded by the National Cancer Institute. His focused approach involved identifying uniquely spliced mRNA messages that were consistently present across multiple biopsies within the same tumor and, more importantly, across a significant number of different patients. The initial analysis spanned a diverse range of cancer types, including prostate, liver, colon, stomach, kidney, and lung cancers.
In parallel, Dr. Kwok collaborated with the UCSF Brain Tumor Center. This partnership allowed for the examination of glioma samples generously donated by 51 UCSF patients. The researchers meticulously collected up to ten biopsies from each tumor, carefully documenting the precise location of each biopsy within the tumor. This detailed spatial information was crucial for ensuring the accuracy of their analysis of unusual mRNA sequences.
Unveiling a Thousand New Candidates: A Milestone in Cancer Research
This comprehensive analysis yielded a remarkable outcome: the identification of nearly 1,000 cancer-specific mRNA molecules. These newly identified molecules were found to be common across various tumors, different cancer types, and numerous patients, yet they had never been previously documented in scientific literature. Crucially, extensive screening confirmed that none of these novel mRNA molecules were present in any healthy tissue samples. This unprecedented discovery provided a rich pool of potential targets for immunotherapy development.
From Candidate to Therapy: Predicting and Validating Immunotherapy Targets
The path from identifying a promising mRNA molecule to developing a viable immunotherapy target is complex and multifaceted. Not every mRNA transcript ultimately translates into a protein. Even if a protein is produced, it may not be presented on the cell surface as an antigen. Furthermore, not all antigens are capable of eliciting an immune response. Therefore, the research team employed sophisticated computational modeling to predict which of the identified mRNA molecules had the highest likelihood of becoming effective immunotherapy targets.
This rigorous filtering process narrowed the field down to 32 promising antigen candidates, all originating from the aberrant RNA splicing characteristic of cancer cells. The researchers then selected the top four candidates for more intensive investigation, based on their potential to provoke an immune attack. These four antigens exhibited structural similarities to other known antigens that effectively trigger immune responses, suggesting their potential efficacy.
The next critical step involved experimentally validating these candidates. The researchers first engineered cells to express these four antigens on their surface. Subsequently, they exposed immune cells, obtained from healthy donor blood, to these antigen-presenting cells. This crucial experiment revealed the presence of specific receptors on these natural immune cells that were capable of reliably detecting the cancerous antigens. This discovery was a vital precursor to engineering these receptors into a therapeutic agent.
The probability of finding such complementary immune receptors in donated blood was considered exceptionally low, described by Dr. Okada as "like one in five or 10 million." However, the team’s persistence paid off. For two of the top four antigens, they successfully identified corresponding immune receptors in two different blood donors, a truly significant breakthrough.
Engineering a Novel Immunotherapy: From Lab Bench to Clinical Promise
With the identification of both the cancer-specific antigens and the corresponding immune receptors, the researchers embarked on the creation of a novel immunotherapy. They engineered laboratory T-cells to express these newly discovered immune receptors. These specially trained T-cells were then unleashed upon glioma cells cultured in petri dishes. The results were striking: the engineered T-cells proved highly effective, swiftly identifying and eradicating the cancer cells.
This laboratory success marks a pivotal moment, demonstrating the tangible potential of this novel approach. The UCSF team is now actively progressing this research into animal models of cancer. If these preclinical studies prove successful, they aim to expedite the translation of this therapy to human patients. The vast dataset generated by this study contains information on numerous other potential antigens, including the 28 that did not make the final selection in this particular study, and countless others yet to be discovered. This wealth of data ensures a continuous pipeline of research and development.
The precise reasons why so many cancers converge on producing the same limited set of "jumbled" proteins remain a subject of ongoing scientific inquiry. It is possible that these altered splicing patterns are an inherent byproduct of the complex biological processes that drive cancer development. Regardless of the underlying cause, this research has undeniably opened a new and promising front in the ongoing battle against cancer.
Reflecting on the collaborative nature of this achievement, Dr. Okada highlighted the interdisciplinary synergy at UCSF. "This advance for cancer patients is the epitome of collaboration at UCSF, from computational modeling to laboratory validation and new techniques in brain surgery," he stated. "It’s exactly what the field needs to overcome the most stubborn cancer cases and bring relief to our patients." This collaborative spirit, bridging diverse scientific disciplines, is often the catalyst for transformative breakthroughs in medicine. The successful identification of novel, cancer-specific antigens derived from altered RNA splicing represents a significant stride forward, offering a tangible path toward more effective and targeted immunotherapies for a wide range of challenging cancers.
